- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07951398
Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Young Children With Functional Constipation: a Prospective Comparative Study (BC-LGG-FC)
Bacillus Clausii or Lactobacillus Rhamnosus GG Added to Dietary Management in Children Aged 12-48 Months With Functional Constipation: A Prospective, Open-Label, Three-Arm Comparative Study
This prospective study compared Bacillus clausii and Lactobacillus rhamnosus GG, each added to dietary management, with dietary management alone in children aged 12-48 months with functional constipation (Rome IV). Children assigned to probiotic treatment were randomly allocated to Bacillus clausii or Lactobacillus rhamnosus GG (2 × 10⁹ spores or CFU daily for two months); consecutive children receiving dietary management alone served as controls. Defecation frequency, stool consistency, painful defecation and abdominal distension were assessed at baseline and at months 1 and 2.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
This prospective, open-label, three-arm comparative study was conducted at the pediatric gastroenterology outpatient clinic of Gaziosmanpaşa Taksim Training and Research Hospital, Istanbul, Türkiye, between February 2020 and July 2021.
Allocation: Children assigned to probiotic treatment were randomly allocated in a 1:1 ratio to the Bacillus clausii (BC) or Lactobacillus rhamnosus GG (LGG) group according to a computer-generated randomization list. The control group consisted of consecutive eligible children who presented during the same period and received dietary management alone; this group was not part of the randomization. No placebo was used, and caregivers and investigators were aware of group assignment.
Interventions: Children in the BC group received an oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial (Enterogermina®, Sanofi S.p.A., Italy), one vial once daily. Children in the LGG group received oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops (Maflor®, Mamsel İlaç San. ve Tic. A.Ş., Türkiye), 12 drops once daily (2 × 10⁹ CFU/day). Both probiotics were administered for two months. All children, including those in the control group, received an individualized, age- and weight-appropriate fiber-rich diet plan together with advice on age-appropriate fluid intake. No laxatives or other pharmacological treatments for constipation were given.
Assessments: Weekly defecation frequency (caregiver stool diary), stool consistency (modified Bristol Stool Form Scale for children), painful defecation and abdominal distension were recorded at baseline and at months 1 and 2. Adherence to the probiotic and dietary recommendations was assessed by caregiver report at each follow-up visit.
Outcomes: The primary outcomes were weekly defecation frequency and the presence of painful defecation at month 2. Secondary outcomes were weekly defecation frequency at month 1, stool consistency at months 1 and 2, painful defecation at month 1 and abdominal distension at months 1 and 2.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Istanbul, Turkki (Türkiye), 34295
- Department of Pediatrics, Faculty of Medicine, Biruni University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Age 12 to 48 months
- Functional constipation according to the Rome IV criteria for infants and toddlers (criterion G7): at least two of the following for at least one month: two or fewer defecations per week; history of excessive stool retention; history of painful or hard bowel movements; history of large-diameter stools; presence of a large fecal mass in the rectum. In toilet-trained children, at least one episode per week of incontinence after the acquisition of toileting skills and a history of large-diameter stools that may obstruct the toilet were also considered.
- Written informed consent from a parent or legal guardian
Exclusion Criteria:
- Organic cause of constipation (Hirschsprung disease, anorectal malformation, hypothyroidism, celiac disease, or a spinal or neuromuscular disorder)
- Developmental delay
- Previous gastrointestinal surgery
- Use of probiotics, laxatives or antibiotics within the preceding 8 weeks
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Bacillus clausii + dietary management
Bacillus clausii oral suspension, 2 × 10⁹ spores (one 5-mL vial) once daily for 2 months, in addition to individualized dietary management. |
Oral suspension containing 2 × 10⁹ Bacillus clausii spores per 5-mL vial; one vial once daily for 2 months.
Muut nimet:
Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake. |
|
Kokeellinen: Lactobacillus rhamnosus GG + dietary management
Lactobacillus rhamnosus GG oral drops, 2 × 10⁹ CFU (12 drops) once daily for 2 months, in addition to individualized dietary management. |
Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake. Oral drops containing 1 × 10⁹ CFU of Lactobacillus rhamnosus GG (ATCC 53103) per 6 drops; 12 drops once daily (2 × 10⁹ CFU/day) for 2 months.
Muut nimet:
|
|
Active Comparator: Dietary management alone
Individualized dietary management without a probiotic. Consecutive eligible children presenting during the same period; not randomized. |
Individualized fiber-rich diet plan appropriate for age and body weight, with advice on age-appropriate fluid intake. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Weekly defecation frequency
Aikaikkuna: 2 months after the start of treatment
|
Number of bowel movements per week, recorded from a stool diary kept by the caregiver. |
2 months after the start of treatment
|
|
Proportion of children with painful defecation
Aikaikkuna: 2 months after the start of treatment
|
Presence or absence of painful defecation, based on caregiver report at the follow-up visit |
2 months after the start of treatment
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Weekly defecation frequency
Aikaikkuna: 1 month after the start of treatment
|
Number of bowel movements per week, recorded from a stool diary kept by the caregiver. |
1 month after the start of treatment
|
|
Stool consistency (modified Bristol Stool Form Scale for children)
Aikaikkuna: 1 month and 2 months after the start of treatment
|
Caregiver-rated stool form using the modified Bristol Stool Form Scale for children; higher scores indicate softer stools. |
1 month and 2 months after the start of treatment
|
|
Proportion of children with painful defecation
Aikaikkuna: 1 month after the start of treatment
|
Presence or absence of painful defecation, based on caregiver report at the follow-up visit. |
1 month after the start of treatment
|
|
Proportion of children with abdominal distension
Aikaikkuna: 1 month and 2 months after the start of treatment
|
Presence or absence of abdominal distension, assessed at the follow-up visit. |
1 month and 2 months after the start of treatment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: ABDULLAH SERT, Department of Pediatrics, Faculty of Medicine, Biruni University
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood Functional Gastrointestinal Disorders: Neonate/Toddler. Gastroenterology. 2016 Feb 15:S0016-5085(16)00182-7. doi: 10.1053/j.gastro.2016.02.016. Online ahead of print.
- Lane MM, Czyzewski DI, Chumpitazi BP, Shulman RJ. Reliability and validity of a modified Bristol Stool Form Scale for children. J Pediatr. 2011 Sep;159(3):437-441.e1. doi: 10.1016/j.jpeds.2011.03.002. Epub 2011 Apr 13.
- Lojanatorn P, Phrommas J, Tanpowpong P, Getsuwan S, Lertudomphonwanit C, Treepongkaruna S. Efficacy of Bacillus clausii in Pediatric Functional Constipation: A Pilot of a Randomized, Double-Blind, Placebo-Controlled Trial. Indian Pediatr. 2023 Jun 15;60(6):453-458. Epub 2023 Feb 9.
- Gordon M, de Geus A, Boruta M, Banasiuk M, Benninga M, Borrelli O, Darbari A, Dore-Stites D, Gould M, Hawa J, Jones K, Kilgore A, Mousa H, Nurko S, Thapar N, Khlevner J, Sinopoulou V, Tabbers M. European Society for Paediatric Gastroenterology, Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0-18 years. J Pediatr Gastroenterol Nutr. 2026 Aug;83(2):335-366. doi: 10.1002/jpn3.70447. Epub 2026 May 20.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- KAEK-151-2019
- Ethics decision 151/2019 (Muu tunniste: Taksim Training and Research Hospital Clinical Research Ethics Committee)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
De-identified individual participant data underlying the reported results will be available from the corresponding author upon reasonable request.
IPD-jaon aikakehys
Beginning after publication of the article, with no planned end date.
IPD-jaon käyttöoikeuskriteerit
De-identified individual participant data underlying the reported results will be available to researchers who provide a methodologically sound proposal. Requests should be directed to the corresponding author (asert@biruni.edu.tr); data will be shared after approval of the request and a data-sharing agreement.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .